Pipeline.
WeWe areare buildingbuilding aa portfolioportfolio ofof novel,novel, differentiateddifferentiated GPCRGPCR biologics.biologics.
WeWe areare buildingbuilding aa portfolioportfolio ofof novel,novel, differentiateddifferentiated GPCRGPCR biologics.biologics.
WeWe areare buildingbuilding aa portfolioportfolio ofof novel,novel, differentiateddifferentiated GPCRGPCR biologics.biologics.
Program
Target class
Status
Stage
Discovery
Lead ID
pRECLINICAL
IND-E
Oncology
CPI Agonist
GlobalBio
Oncology
GlobalBio
CPI Agonist
Discovery
Lead ID
pRECLINICAL
IND-E
Oncology
CPI Agonist
GlobalBio
Cardiovascular
Thrombosis
GPCR Antagonist
Wholly-owned
Cardiovascular
Wholly-owned
GPCR Antagonist
Discovery
Lead ID
pRECLINICAL
IND-E
Cardiovascular
Thrombosis
GPCR Antagonist
Wholly-owned
Oncology
TMP ANTAGONIST
Top 20 Pharma
Oncology
Top 20 Pharma
TMP ANTAGONIST
Discovery
Lead ID
pRECLINICAL
IND-E
Oncology
TMP ANTAGONIST
Top 20 Pharma
CNS
GPCR Antagonist
Top 20 Pharma
CNS
Top 20 Pharma
GPCR Antagonist
Discovery
Lead ID
pRECLINICAL
IND-E
CNS
GPCR Antagonist
Top 20 Pharma
Undisclosed
GPCR Agonist
Nxera
Undisclosed
Nxera
GPCR Agonist
Discovery
Lead ID
pRECLINICAL
IND-E
Undisclosed
GPCR Agonist
Nxera
Fibrosis
IPF
GPCR Antagonist
Wholly-owned
Fibrosis
Wholly-owned
GPCR Antagonist
Discovery
Lead ID
pRECLINICAL
IND-E
Fibrosis
IPF
GPCR Antagonist
Wholly-owned
Cardiometabolic
Mash
TMR Agonist
Wholly-owned
Cardiometabolic
Wholly-owned
TMR Agonist
Discovery
Lead ID
pRECLINICAL
IND-E
Cardiometabolic
Mash
TMR Agonist
Wholly-owned
©2026 Antiverse. All rights reserved.
©2026 Antiverse. All rights reserved.
©2026 Antiverse. All rights reserved.